Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy.
about
L-citrulline provides a novel strategy for treating chronic pulmonary hypertension in newborn infantsTreatment-related biomarkers in pulmonary hypertensionIncreased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1.AMBITION: An important piece in the therapeutic puzzle of pulmonary arterial hypertension.Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertensionExhaled nitric oxide in diagnosis and management of respiratory diseases.Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells.Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension.Arginine metabolic endotypes in pulmonary arterial hypertension.An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.Alterations of cellular bioenergetics in pulmonary artery endothelial cellsHigher urine nitric oxide is associated with improved outcomes in patients with acute lung injury.Increased exhaled nitric oxide levels after exercise in patients with chronic systolic heart failure with pulmonary venous hypertension.Update in pulmonary hypertension 2005.Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.Sildenafil Reduces Inflammation and Prevents Pulmonary Arterial Remodeling of the Monocrotaline - induced Disease in the Wistar Rats.An Overview of Fractional Exhaled Nitric Oxide and Children with AsthmaPossible role of nitric oxide in the pathogenesis of pulmonary hypertension in broilers: a synopsis.High levels of hyaluronan in idiopathic pulmonary arterial hypertension.Phosphorylation inactivation of endothelial nitric oxide synthesis in pulmonary arterial hypertension.Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension.HIF2α-arginase axis is essential for the development of pulmonary hypertension.Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging.Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques.Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosisBreath analysis in pulmonary arterial hypertension.Combination therapy in pulmonary arterial hypertension: do we have the right strategy?Endothelial cell energy metabolism, proliferation, and apoptosis in pulmonary hypertension.Application of nitric oxide measurements in clinical conditions beyond asthma.Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.Decreased exhaled nitric oxide levels in patients with mitochondrial disordersRiociguat: PATENT-1 Study.L-arginine restores endothelial nitric oxide synthase-coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats.Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.A urinary test for pulmonary arterial hypertension?Inhibition of nitric oxide synthase unmasks vigorous vasoconstriction in established pulmonary arterial hypertension.Fractional Exhaled Nitric Oxide Measurement in Pulmonary Hypertension: A Follow-Up Study.Mitochondrial dysfunction and pulmonary hypertension: Cause, Effect or Both.
P2860
Q26829856-9B4F0399-B658-4D01-9EFE-B54C2A74EACDQ28081276-6BA09194-176D-495A-AA92-D94A6B5E459BQ33265103-E586BE76-046E-49FB-A6E7-394EAECA1ADEQ33362326-EEEF0FF5-9352-4F12-A330-1302D822D3C2Q33372442-5B33869E-5E5A-4DDC-8687-052DAD619766Q33568617-BAE63D30-D640-43C0-BF6D-6CFA4CFD48FAQ33703652-F02C3EA3-C8C9-4BF2-A701-1AD4D48814EBQ33892575-0BA56EAA-7192-4479-B922-F38CE1C2FED1Q35153029-5AE656DB-0B09-4A60-BE0E-2468A735F5EEQ35517452-1092E43C-9E73-489D-A1EE-EFD17EAE1A92Q35534747-3F9802A5-B108-4A96-A82F-430757623A87Q35611704-767C75CC-C0DF-401F-B86E-389763B1A49BQ35855126-FEC48BCA-EEDD-4FE4-A77B-7888D5C89356Q36303871-87DDEEA5-3FF5-4CF7-BF9F-F8B1301BE185Q36403168-8F0BEF07-F85F-4F41-A48B-A98D1F0A5D04Q36543145-9058598C-1317-4092-99F2-44E2D837840DQ36568847-DD87DCAB-50E7-4B95-9E2A-C6AFCB3F3C72Q36814010-9807703F-C6A3-4753-95DA-3DD5A906BF65Q36874431-A84BFD75-8AA4-4EE2-BE87-7F1D4D64F7DCQ36977316-50B6A091-8B85-4203-9B48-DEE780309AD1Q37071749-54D5D667-A9A8-4D8C-A4E7-7CA0A5F8F546Q37112033-11C0B9C7-AA47-4D3E-AD51-9A12C666B6EDQ37161630-2AB5B519-382E-4AA1-9320-5A789F32BA83Q37406369-202CE22C-3196-4D6A-855B-E4F7AC8FF81EQ37406383-25514347-6B5A-4A2C-B76E-96DE9B8B0FD0Q37555347-17CA1761-0C3A-49EA-B77D-2DBD131BE03BQ37555421-746F4C53-0140-48E0-A95A-7F9F81EE40B8Q37615204-A54BEEC6-3FEE-4AFC-8C5B-673F1E3EF73BQ37867668-9B1D66A4-005B-4469-8583-1A81A2D628CAQ38112040-49A10FB3-ED83-43B1-A551-6F162C7E99E9Q38670757-C4D2E752-A0EC-4E94-8888-8BFF584F3227Q40919790-609C4414-3708-4102-8698-D67BEC6E21BEQ41811395-077087D7-86CE-415B-B31D-C423C871F77EQ41980644-86359B09-D14E-4CEC-BD7D-74F57337BAAFQ43136761-4A2B4F51-1AFA-4D78-BFB7-5A909DD01D9BQ45198254-073DC9DD-8F6A-4336-A5BD-8297DF589AECQ46616178-72A1F06F-C5E8-4D65-878F-4587383B2E40Q47111545-A8E9B5E4-1E92-4C00-A773-5DD404BA0BA9Q47398434-E169919D-6AE4-45E6-BAB6-67C500D810BAQ47726007-8480D736-21E3-44C7-85B0-2CECA55E7A46
P2860
Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Decreased exhaled nitric oxide ...... response to bosentan therapy.
@en
Decreased exhaled nitric oxide ...... response to bosentan therapy.
@nl
type
label
Decreased exhaled nitric oxide ...... response to bosentan therapy.
@en
Decreased exhaled nitric oxide ...... response to bosentan therapy.
@nl
prefLabel
Decreased exhaled nitric oxide ...... response to bosentan therapy.
@en
Decreased exhaled nitric oxide ...... response to bosentan therapy.
@nl
P2093
P2860
P1476
Decreased exhaled nitric oxide ...... response to bosentan therapy.
@en
P2093
Gregory B Diette
Hunter C Champion
J T Sylvester
Reda E Girgis
Roger A Johns
Solbert Permutt
P2860
P304
P356
10.1164/RCCM.200412-1684OC
P407
P577
2005-05-05T00:00:00Z